Filing summary: 10-Q for the quarter ended March 31, 2022
Issuer identity: The supplied filing is for IMARA Inc. (Nasdaq: IMRA), not Enliven Therapeutics, Inc. Verify that this is the intended filing before relying on the summary.
Business context
IMARA was a clinical-stage biopharmaceutical company with no approved products and no product revenue. The filing reports first-quarter 2022 results and was signed May 6, 2022. In April 2022, after interim trial analyses, the company decided to stop developing tovinontrine (IMR-687) in sickle cell disease, beta-thalassemia and heart failure with preserved ejection fraction, and to discontinue development plans for IMR-261. It said it was not then developing any product candidates and was assessing strategic options.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $11.2 million | $7.1 million |
| General and administrative expense | $3.5 million | $3.2 million |
| Total operating expenses / operating loss | $14.7 million | $10.3 million |
| Net loss | $14.6 million | $10.3 million |
| Net loss per share, basic and diluted | $0.56 | $0.58 |
| Cash used in operating activities | $17.2 million | $13.0 million |
As of March 31, 2022, cash, cash equivalents and short-term investments totaled $72.9 million, down from $90.3 million at December 31, 2021. Total assets were $81.6 million; accumulated deficit was $162.1 million. The balance sheet reported no borrowings or other financial debt, but did report operating lease liabilities totaling $2.5 million, including current and non-current portions. First-quarter comprehensive loss was $14.7 million. Margins are not meaningful because the company had no revenue.
Material changes, outlook and risks
- Operating expenses rose $4.4 million year over year, primarily because R&D increased $4.1 million as trial, clinical-material and manufacturing costs rose. Net loss widened by $4.4 million.
- Management expected R&D and G&A expenses to decrease significantly beginning in the second half of 2022 after the April program discontinuations and workforce reduction. The filing cautions that expected savings may not be achieved and that trial wind-down costs were not yet determinable.
- On April 12, the board approved an approximately 83% workforce reduction, leaving six full-time employees. The reduction was expected to be substantially completed by the end of Q2 2022. The company estimated a one-time Q2 restructuring charge of $2.0 million to $2.2 million, primarily for employee-related costs.
- Management believed March 31 cash, cash equivalents and investments would fund operating and capital needs for at least 12 months from the filing date. That estimate depends on assumptions; the company said further product development would require additional funding. It had no credit facility or committed external funding source.
- The company was evaluating strategic options, which could include a transaction, sale, wind-down or liquidation. It gave no assurance that a transaction would occur or deliver value. Continued evaluation and operating costs could reduce cash available to stockholders; any liquidation distribution would depend on timing and obligations or reserves.
- Other disclosed risks include clinical-trial termination costs, retention of remaining employees, potential inability to raise capital, COVID-19-related disruption and investment interest-rate sensitivity. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer: the filing is IMARA Inc., although the request names Enliven Therapeutics, Inc.
- Review the full interim trial results and the basis for discontinuing tovinontrine and IMR-261; the filing says Ardent’s high-dose VOC difference versus placebo was not statistically significant, and Forte showed no meaningful benefit in transfusion burden or most reported biomarkers.
- Track actual cash burn, trial close-out costs, restructuring charges and realized savings against management’s at-least-12-month runway estimate.
- Monitor the strategic-options process, remaining employee retention, and any transaction, wind-down or liquidation decision and its potential costs and stockholder proceeds.
- Check subsequent filings for changes in cash, liabilities, share count, and any new financing or material contingencies.